Renalytix (

1. 02 Oct 26
   SIGNAL 1 Activist stake

   Harwood Capital LLP*, Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood – Purchase of Ordinary Shares; 1,166,667

   Director/PDMR Shareholding (Replacement) · RNS 9805076 ↗
2. 01 Oct 26
   Director/PDMR Shareholding Director buysActivist stake

   LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills,...

   RNS 9802753 ↗
3. 28 Sep 26
   Result of General Meeting

   LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all resolutions were passed.

   RNS 9794377 ↗
4. 28 Sep 26
   Directorate Change

   Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that Julian Baines MBE has indicated his intention to stand down as Non-Executive Chair of Renalytix on 31 December 2026.

   RNS 9792805 ↗
5. 25 Sep 26
   Investor Presentations

   LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next week and will be presenting at the...

   RNS 9792120 ↗
6. 16 Sep 26
   Additional CEO Share Purchase

   LONDON and NEW YORK, 16 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 11 September and 15 September 2026 James McCullough, Chief Executive Officer, bought a...

   RNS 9775262 ↗
7. 14 Sep 26
   New Accounting Ref Date

   Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that it has resolved to change the Company's accounting reference date.

   RNS 9770310 ↗
8. 11 Sep 26
   CEO Share Purchase

   LONDON and NEW YORK, 11 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 8 September 2026 and 9 September 2026 James McCullough, Chief Executive Officer, bought...

   RNS 9766690 ↗
9. 08 Sep 26
   Capital Access Window - Renalytix Plc

   RNS 9760526 ↗
10. 08 Sep 26
    Result of WRAP Retail Offer

    Renalytix is pleased to announce, further to its announcement of 3 September 2026, the completion of the WRAP Retail Offer at an issue price of £0.06 per Ordinary Share (the "Placing Price").

    RNS 9759852 ↗
11. 03 Sep 26
    WRAP Retail Offer for up to £1,000,000

    Renalytix is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £1,000,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares").

    RNS 9753045 ↗
12. 03 Sep 26
    Result of Fundraise

    Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, confirms that, further to the Company's announcement released at 7.01 a.m. on 1 September 2026 (RNS Number: 8254S) (the "Fundraising...

    RNS 9752873 ↗
13. 01 Sep 26
    Capital Access Window - Renalytix plc

    RNS 9748669 ↗
14. 01 Sep 26
    Proposed Fundraise

    596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR").

    RNS 9747833 ↗
15. 01 Sep 26
    Collaboration with Quest Diagnostics

    Collaboration with Quest Diagnostics to expand kidneyintelX.dkdTM testing in the United States

    RNS 9747173 ↗
16. 24 Aug 26
    AIM Rule 17 Disclosure

    LONDON and NEW YORK, 24 August 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, provides the following update pursuant to Rule 17 and Schedule 2 (g) (v) of the AIM Rules.

    RNS 9737226 ↗
17. 30 Jun 26
    Real world evidence study data published

    · Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk prognosis, improvements in kidney function, increases in guideline-directed therapy uptake, and measurable reduction in individual patient risk trajectories over 24 months

    RNS 9643051 ↗
18. 22 Apr 26
    Key milestones achieved for kidneyintelX.dkd

    Key regulatory milestones achieved in support of scaling of kidneyintelX.dkd

    RNS 9531549 ↗
19. 26 Mar 26
    Half-year Results

    LONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9492532 ↗
20. 13 Feb 26
    Further CEO Share Purchase

    LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9430854 ↗
21. 13 Feb 26
    Director/PDMR Shareholding Director buys

    LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9429127 ↗
22. 12 Feb 26
    Director/PDMR Share Purchase Director buys

    LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9427087 ↗
23. 12 Feb 26
    CEO Share Purchase

    LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9426863 ↗
24. 11 Feb 26
    H1 Trading update

    LONDON and NEW YORK, 11 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...

    RNS 9424676 ↗
25. 12 Jan 26
    Three kidneyintelX.dkd Clinical Integrations

    LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...

    RNS 9346467 ↗
26. 09 Dec 25
    AGM Statement

    LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...

    RNS 9283718 ↗
27. 25 Nov 25
    Plan to Implement ADS Ratio Change

    Renalytix Announces Plan to Implement ADS Ratio Change

    RNS 9254648 ↗
28. 12 Nov 25
    Pivotal kidneyintelX.dkd data published

    Pivotal kidneyintelX.dkd data published in Diabetes Care Journal of the American Diabetes Association

    RNS 9227737 ↗
29. 03 Nov 25
    Audited Full Year Fiscal 2025 Results

    LONDON and NEW YORK, 3 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...

    RNS 9207450 ↗
30. 27 Oct 25
    Confirmation of receipt of £860k R&D tax credits

    Confirmation of receipt of £860k of R&D tax credits

    RNS 9195035 ↗
31. 10 Oct 25
    $4m balance sheet improvement with bond conversion

    The conversion of the Convertible Bonds will provide a significant improvement to Renalytix's balance sheet, improving the Company's net asset position by approximately $4m and saving up to $1.4m in accrued interest over the remaining life of the loan.

    RNS 9162285 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.